Aussies to get free UQ COVID vaccine

Aussies to get free UQ COVID vaccine

Morrison's announcement on Monday that Australia would also purchase the CSL drug if trials proved successful appeared to be the culmination of a deal to get both vaccines across the line.

Under the deals, which are worth A$1.7 billion ($1.2 billion), Australia will receive the first doses of candidate vaccines being developed by the universities if trials prove successful.

"If data from phase three trials shows the vaccines are effective and safe, the first vaccines could be approved at the beginning of the year, possibly with conditions attached", Institute president Klaus Cichutek said.

Some 84.8 million vaccine doses would be manufactured, primarily in Melbourne by CSL, which plans to produce 51 million doses of a UQ vaccine and 33.8 million doses of an Oxford vaccine under a heads of agreement signed with the government.

The AstraZeneca vaccine is now the most progressed candidate in the world, with late-stage phase three trials in Britain, Brazil, the United States and South Africa generating strong immune responses in humans with no significant concerns.

Orozco mentioned that the vaccine developed by the private firm Laboratorio Avimex with the scientists from Mexico's main public university, UNAM, and the Mexican Social Security Institute, is ready for starting the first phase of testing with humans.

"There are no mechanisms for "compulsory".

The HoA is between CSL's influenza vaccines company, Seqirus, who will hold regulatory responsibility as the marketing authorisation holder, and the Australian Government.

J&J's vaccine is one of over a hundred worldwide being developed in response to the coronavirus pandemic, which has infected almost 26.5 million people and led to some 869,323 deaths. "All the results so far indicate good safety, tolerability and effectiveness", he said of the CureVac mRNA vaccine candidate.

Late stage phase 3 trials are underway for the Oxford vaccine. The federal government has the option to order 200 million more doses.

In addition, it is looking to participate in Phase 3 trials with French drugmaker Sanofi SA and Johnson & Johnson's Janssen unit and Chinese companies CanSino Biologics Inc. and Walvax Biotechnology Co.

"Any decisions regarding vaccines will be based on the advice of the Australian Technical Advisory Group on Immunisation and other experts, and will be contingent on a vaccine meeting all requirements with regard to testing and safety".

Related Articles